CDEK by Data4ThePeople

Sign in Sign up

← All organizations

Axaron Bioscience AG

For profit

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 2

First clinical trial

Last known activity

Dec 1, 2004

Acquired by Sygnis Bioscience GmbH & Co KG → Expedeon on Jul 5, 2006

Timeline

1990s

Jun 1, 1997
Axaron Bioscience AG— Founded

2000s

Jul 5, 2006
Sygnis Bioscience GmbH & Co KG— Acquired By

2010s

Jun 26, 2017
Expedeon— Now

Drugs by trial phase (1 distinct, 1 trials)

Phase 2 (1 own, 0 via acquisition)

sargramostim

Indications

Studied for

Stroke

Recent trials (1)

NCT00132470Lead sponsorPhase 2Dec 1, 2004

Details

Founded: Heidelberg, DE Jun 1, 1997
Last known activity: Dec 1, 2004